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Ⅰ. INTRODUCTION
Lymphomatoid granulomatosis (LYG) is an uncommon 
type of EBV-associated B-cell lymphoproliferative disorder 
(LPD) which commonly arises in various immunosuppressive 
conditions1). It primarily affects the lung, while it may be 
concurrently present in other multiple sites such as the skin, 
central nervous system, kidney, gastrointestinal tract, nose, 
eyes, liver and oral cavity2,3). Solitary extrapulmonary lesions 
are extremely rare and are considered as an aspect of 
dissemination and systemic involvement1,2,4). There have 
been a few reports on nervous, cutaneous and oral LYG 
lesions without a pulmonary lesion development at the time 
of diagnosis5-7). Whether the extrapulmonary lesions represent 
an initial sign of systemic disease, or are a true solitary 
lesion is controversial.
Herein, we report a solitary oral LYG in a patient taking 
methotrexate (MTX). The initial clinical impression for the 
oral lesion was Medication-related osteonecrosis of the jaw 
(MRONJ), while the primary pathologic diagnosis was natural 
killer (NK)/T-cell lymphoma. We discussed the differential 
diagnosis of LYG and reviewed the former literature.
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Lymphomatoid granulomatosis (LYG) is an uncommon Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorder distinct
from lymphoma. LYG primarily occurs in the lung with or without accompanied lesions in the skin, central nervous system, kidney,
gastrointestinal tract, nose, eyes, liver and oral cavity. Solitary extrapulmonary LYG is extremely rare, and whether solitary lesions progress
onto pulmonary development and dysfunction is controversial. Herein, we report a case on a solitary LYG in the maxilla gingiva with 
bone exposure in a patient who had been taking methotrexate for rheumatoid arthritis.
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Ⅱ. CASE REPORT
A 71-year-old female was referred to our hospital from 
a primary dental clinic for complaints of discomfort at the 
maxillary right first molar region. Oral examination revealed 
gingival necrosis with alveolar bone exposure at the 
posterior of right maxillary first molar (Fig. 1A). Redness 
and mild swelling were observed at the marginal gingiva 
of right maxillary second premolar and first molar. Both 
teeth had a history of root canal treatment received 5 
months ago and showed bad periodontal condition with 
cortical bone loss and tooth mobility (Fig. 2A and B). The 
right maxillary second molar had been missing for more 
than 10 years.
She was on medication for hypertension (amlodipine), 
rheumatoid arthritis (methotrexate [MTX], 10mg weekly for 14 
years and bucillamine) and had been taking bisphosphonate 
by oral administration for 5 months. She had a past history 
of recurrent pulmonary tuberculosis treated 30 years ago. 
The possibility of MRONJ first came to our mind, because 
the patient was an elderly-women taking bisphosphonate 
and had signs of bone exposure and resorption. Additional 
radiologic and laboratory tests were made. Multi-detector 
computed tomography (MDCT) was taken on the maxilla, 
and C-terminal telopeptide (CTX) and osteocalcin serum 
level tests were evaluated. For her well-being, cefpodoxime, 
metronidazole and nonsteroidal anti-inflammatory drugs (NSAIDs) 
were prescribed to decrease the pain and inflammation. 
A week later, pain symptoms had reduced since the last 
visit and inflammation signs had been diminished at the site. 
The CTX level was 0.296 and osteocalcin level was 19.50. 
The CT image informed that there was cortical bone loss 
and adjacent soft tissue lesion on the right maxillary second 
premolar and first molar (Fig. 2C and D). The Department 
of Oral and Maxillofacial Radiology recommended a biopsy 
on the lesion to distinguish between inflammatory disease 
Fig. 1. Clinical image of the right maxillary lesion. A. 1st visit. 
Ulceration and bone exposure were observed in the 
posterior of #16. Redness and swelling were seen in 
the palatal marginal gingiva. B. 4 weeks after the 1st
visit. The lesion showed improvement with healing of 
the ulcer. C. 6 weeks after the 1st visit. The lesion 
was aggravated on the palatal side and re-biopsy was 
done. D. 9 weeks after the 1st visit. The necrotic area 
was partially reduced. E. 15weeks after the 1st visit. 
Necrosis had disappeared, and mild redness was observed.
F. 18 weeks after the 1st visit. Only a mild indentation 
of the former lesion was observed. 
Fig. 2. A. Panoramic view taken on the 1st visit. B. Periapical 
view taken on the 1st visit. The right maxillary second 
premolar and first molar showed cortical bone loss. 
C. Bone window coronal view of maxillary computed 
tomography (CT) taken on the 1st visit. D. Bone window
axial view of maxillary CT taken on the 1st visit. Cortical
bone loss was observed at the buccal side of the right maxillary
second premolar and first molar. E. F18-fluorodeoxyglucose
(FDG) positron emission tomography (PET)/CT axial view
showed a hot spot at the right posterior maxilla. 
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and malignancy. A biopsy was performed on the gingiva 
avoiding necrosis and necrosis-adjacent tissue. The biopsy 
specimen revealed chronic non-specific inflammation. The 
plan was to maintain the antibiotics and NSAIDs to reduce 
the inflammation. 
Four weeks after the first visit, bone exposure had decreased, 
and inflammatory signs were alleviated but not yet terminated 
at the lesion site (Fig. 1B). However, during the next two 
weeks, the lesion aggravated at the adjacent palatal gingiva 
with diffuse ulceration and necrosis (Fig. 1C) and re-biopsy 
was performed near the necrosis. The patient complained 
of severe pain and informed us that she had not been taking 
her MTX prescription after the first visit. MTX withdrawal 
had been directed by her primary dentist and rheumatologist 
in fear of MTX associated MRONJ which has been reported 
before8). The two clinicians were not aware of the bisphosphonate 
prescription which had been made in another hospital, so 
it had been maintained despite the possibility of MRONJ. 
Pathologic evaluation revealed areas of severe necrosis 
and cell-rich portions (Fig 3A). The cell-rich portions were 
composed of monocytes, predominantly lymphocytes infiltrating 
the adjacent tissue (Fig. 3B). Characteristically, the lymphocytes 
frequently displayed an angiocentric pattern and angioinvasive 
properties (Fig. 3C). The lymphocytes were a mixture of 
large atypical lymphocytes and small lymphocytes (Fig. 
3D). Other than the lymphocytes, plasma cells and other 
inflammatory cells were seen in the background as well. 
NK/T-cell lymphoma was our primary pathologic diagnosis. 
To confirm our diagnosis, molecular pathology staining was 
proceeded. 
By immunohistochemistry, the large atypical lymphocytes 
were revealed to be CD20-positive B cells (Fig. 3E), while 
the small lymphocytes were CD3/T-cell intracytoplasmic 
antigen (TIA)-positive T cells (Fig. 3F and G). The atypical 
B cells were figured to be the main aspect of the lesion, 
while T cells were considered as reactive background. 
Epstein-Barr virus (EBV) infection was confirmed in the 
atypical B cells by in situ hybridization (Fig. 3H) CD56 was 
negative (not shown), which ruled out NK/T-cell lymphoma. 
The final diagnosis was lymphomatoid granulomatosis. It 
was given a grade 3 for the extensive amount of necrosis, 
aggregated large atypical CD20-positive B cells and high 
number of EBV positive cells (50>High power field)9,10). 
Fig. 3. Histopathologic examination and molecular pathology 
results of the surgical specimen. A. Lymphocytic infiltrated
(Ly) on the submucosal area with extensive necrosis 
(Ne) and ulceration (Hematoxylin and eosin [HE], original 
magnification x12.5). B. The lymphocytes have infiltrated
blood vessels (blue arrow) and submucosal adipose tissue. 
Necrosis was noticed (inset) (HE, original magnification
x200, inset x40). C. Angiocentric and angioinvasive infiltration
of lymphocytes in a blood vessel (BV). (HE, original 
magnification x200, inset x400). D. The lymphocytes were
mainly large atypical lymphocytes (green arrow), and 
small reactive lymphocytes (yellow arrow), plasma cells 
and various inflammatory cells were admixed (HE, original
magnification x400). E. Dense infiltration of CD20-positive
large atypical lymphocytes (Immunohistochemistry staining
[IHC], CD20, original magnification x200). F. Reactive CD3- 
positive small lymphocytes. (IHC, CD3, original magnification
x200). G. Reactive lymphocytes are positive on TIA stain
as well. (IHC, TIA, original magnification x200). H. High 
amounts of EBER-positive large lymphocytes are observed,
indicating Epstein-Barr virus infection. (In situ hybridization,
EBER, original magnification x200)
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MTX was considered to be responsible for the immunosuppression 
causing LYG in our patient. The patient was referred to the 
Department of Hemato-oncology for proper management 
and MTX was replaced with tacrolimus. To evaluate presence 
of LYG lesions at other sites, especially the lung, a body 
CT was taken. There were no abnormal findings throughout 
the body CT, other than right kidney’s parenchymal thinning 
on abdomen-pelvis and a post- inflammatory sequela due to 
previous tuberculosis in the chest. There were no abnormal 
lymph nodes on the neck. On Positron emission tomography 
(PET)/CT, focal fludeoxyglucose (FDG) uptake was only observed 
in the right maxilla, regarded as post-operative changes (Fig. 2E).
After replacing MTX to tacrolimus, the lesion gradually 
improved and was almost completely healed by the 2 
month-follow up (Fig. 1D, E, F). Chemotherapy was not 
considered unless the lesion showed recurrence or pulmonary 
lesions occurred.
Ⅲ. DISCUSSION
Oral LYG is extremely rare and may be difficult to diagnose 
at first sight. There have been 11 cases of previously 
reported oral LYG 6,11-19). The clinical features previously 
reported of oral LYG were mainly non-specific (pain, 
granular tissue, ulceration and redness). Other systemic 
features, such as fever, weight loss, fatigue, cough, dysphagia, 
and dysphonia were generally seen in patients with 
synchronous pulmonary lesions6,11). Oral LYG lesions presenting 
as bone exposure with mucosal necrosis, as seen in our 
case, may be difficult to distinguish from MRONJ or deep 
fungal infections (i.e. aspergillosis and zygomycosis)20,21). 
Since the patient had a history of recurrent TB, recurrent 
pulmonary TB and secondary oral TB should had been 
considered for differential diagnosis as well22). Because of 
the low incidence and non-specific clinical features, pathologic 
confirmation is needed for diagnosis, yet pathologic 
differentiation may be challenging as well. 
LYG belongs to the EBV-associated LPD classification and 
needs pathological differentiation with various LPDs and 
other EBV-associated diseases. LYG presents pathologic 
features of large, sometimes atypical B cell infiltrates mixed 
with reactive T cells and other inflammatory cells. Angiocentric 
lymphocytic infiltration and necrosis are commonly observed. 
The large B cells are frequently infected with EBV23). The 
angiocentric and necrotic characteristics of LYG are similar 
to those of NK/T-cell lymphoma24). Abundant amounts of 
reactive T cells in LYG may be confused as T-cell lymphoma, 
especially in early grade 1 lesions with only very few large 
B cells25). The large atypical cells in LYG are CD20-positive 
and CD56-negative (NK-cell-associated marker), which 
distinguishes it from NK/T-cell lymphoma26,27). 
Mononuclear infiltrations with large CD20-positive and 
EBER-positive cells can give the differential diagnosis ranging 
from EBV-associated mucocutaneous ulcer to EBV-associated 
B-cell lymphoma28). The mononuclear infiltration in EBV- 
associated mucocutaneous ulcer is non-tumorous which 
supports the flat and clean clinical appearance of the ulcer. 
Furthermore, Reed-Sternberg like cells are routinely present 
which are not classically noticed in LYG29,30). Occasionally, 
there may be large lesion cells infiltrating blood vessels near 
the surface ulceration in EBV-associated mucocutaneous ulcer30). 
Whether EBV-associated B-cell lymphoma and high-grade 
LYG are a separate classification is a complicated issue. 
Presently, LYG is considered to be distinct from lymphoma, 
yet high-grade LYG does have pathological overlaps with 
subtypes of Diffuse Large B-Cell Lymphoma (DLBCL)23,31,32). 
Angiocentric feature, a characteristic finding of high-grade 
LYG, is not a regular feature of B-cell lymphoma. Lymphomas 
are considered to have a monomorphous cell infiltrate 
distribution compared to the polymorphous background of 
LYG, although polymorphous infiltrates have been noticed 
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within certain lymphomas as well2,25,31,32). In deficient amounts 
of biopsy material, the monomorphous tumor cells-aggregated 
foci may not be included within the captured lesion. 
Therefore, to differentiate LYG from lymphoma a careful 
integrated evaluation of previous lymphoma or immunosuppression 
history, clinical settings (pulmonary and/or multiorgan 
involvement), cellular features and EBV infection status are 
needed9). 
LYG has a wide spectrum of prognosis, from indolent to 
highly progressive, which is difficult to predict at initial 
diagnosis. High-grade LYG resembles the clinical progress 
of lymphoma and generally requires immediate therapy. 
Moreover, further transformation to lymphoma has been 
reported in literature by a rate of 7~45% 1,25,33,34). Meanwhile, 
Katzenstein et al. proposed that grade 2, 3 LYG should be 
termed as “lymphoma” to guide the clinician to select active 
therapeutic options confirmed in lymphoma without risking 
clinical confusion due to the unpredictable biological behavior 
of LYG9). Corticosteroids, immunotherapy and combined 
chemotherapy are the known successful choices to improve 
symptoms of LYG and suspend progression to pulmonary 
dysfunction, the main cause of death3). A low proportion of 
LYG cases, mainly low-grade cases, go through spontaneous 
remission or remission after immunosuppressant discontinuance34,35). 
Persistent methotrexate use has been noticed in cases of 
LYG11,17,35-38). MTX is an anti-metabolic agent with complications 
of bone marrow suppression, and is known possible to 
induce various LPDs39). Among the 12 reported cases of oral 
LYG (including this case), 4 cases had a history of MTX 
prescription11,17). Three of the 4 cases showed complete 
remission after MTX withdrawal even in those with grade 
3 LYG yet lacked long-term follow up data. Successful 
remission after MTX withdrawal has been presented in a 
few cases other than the oral cavity36-38). Nevertheless, 
continuous progression and relapse of LYG are ongoing 
problems in current cohorts and case reports despite the 
chemotherapeutic application in either MTX and non-MTX- 
associated cases11,40,41). Therefore, long term follow-up is 
essential in LYG patients. 
The prognosis of oral LYG patients depends on its 
pulmonary status. When an oral lesion is pathologically 
diagnosed as LYG, a periodic chest evaluation is required 
even in the absence of pulmonary involvement at initial 
examination. Cutaneous LYG lesion preceding its pulmonary 
lesion has been well described4,40,42). Moreover, cutaneous 
lesions are known to present as a first sign of relapse40). 
Our case of oral LYG had alleviated at the first withdrawal 
of MTX but had progressed once again in the adjacent tissue 
during the MTX-free period. The LYG lesion has spontaneously 
regressed since then yet alerts us of the importance of 
periodic check-ups of this disease. The biologic behavior 
of oral lesions is yet poorly understood and its association 
with pulmonary lesion needs further evidence.
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